Xu-Feng Chen (Xufeng Chen)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 3

Top Topics

Prostate Cancer

Endoplasmic Reticulum Stress

Polycystic Ovary Syndrome

Top Venues

Proceedings of the National Academy of Sciences of the United States of America

Science translational medicine

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Chun R Chao, Jeff M Slezak, Kimberly D Siegmund, Kimberly L Cannavale, Yu-Hsiang Shu, Gary W Chien, Xu-Feng Chen, Feng Shi, Nan Song, Stephen K Van den Eeden, Jiaoti Huang
Genome-wide methylation profiling of diagnostic tumor specimens identified DNA methylation markers associated with metastasis among men with untreated localized prostate cancer. Cancer medicine (2023)
Lingfan Xu, Yu Yin, Yanjing Li, Xu-Feng Chen, Yan Chang, Hong Zhang, Juan Liu, James Beasley, Patricia McCaw, Haoyue Zhang, Sarah P Young, Jeff Groth, Qianben Wang, Jason W Locasale, Xia Gao, Dean G Tang, Xuesen Dong, Yiping He, Daniel George, Hailiang Hu, Jiaoti Huang
A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 118 (13) (2021)
Yanjing Li, Yiping He, William Butler, Lingfan Xu, Yan Chang, Kefeng Lei, Hong Zhang, Yinglu Zhou, Allen C Gao, Qingfu Zhang, Daniel G Taylor, Donghui Cheng, Suzette Farber-Katz, Rachid Karam, Tyler Landrith, Bing Li, Sitao Wu, Vickie Hsuan, Qing Yang, Hailiang Hu, Xu-Feng Chen, Melissa Flowers, Shannon J McCall, John K Lee, Bryan A Smith, Jung Wook Park, Andrew S Goldstein, Qianben Wang, Matthew B Rettig, Andrew J Armstrong, Qing Cheng, Jiaoti Huang
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. Science translational medicine 11 (521) (2020)